Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNB4 | P30926 | 4/20 | 0.60 |
| ▸ | CHRNA3 | P32297 | 4/20 | 0.60 |
| ▸ | CHRNB1 | P11230 | 2/20 | 0.60 |
| ▸ | CHRNB2 | P17787 | 2/20 | 0.60 |
| ▸ | CHRNB3 | Q05901 | 2/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL447049 | 1.00 | CHRNB4 (0.60) | CHRNB4CHRNA3CHRNB1CHRNB2CHRNB3 | |
| SCHEMBL450027 | 1.00 | CHRNB4 (0.60) | CHRNB4CHRNA3CHRNB1CHRNB2CHRNB3 | |
| SCHEMBL24565690 | 0.96 | CHRNB4 (0.56) | CHRNB4CHRNA3CHRNB1CHRNB2CHRNB3 | |
| SCHEMBL24565689 | 0.96 | CHRNB4 (0.56) | CHRNB4CHRNA3CHRNB1CHRNB2CHRNB3 | |
| SCHEMBL24565686 | 0.96 | CHRNB4 (0.56) | CHRNB4CHRNA3CHRNB1CHRNB2CHRNB3 | |
| SCHEMBL15037237 | 0.86 | CHRNB4 (0.61) | CHRNB4CHRNA3CHRNB1CHRNB2CHRNB3 | |
| SCHEMBL13867982 | 0.86 | CHRNB4 (0.61) | CHRNB4CHRNA3CHRNB1CHRNB2CHRNB3 | |
| SCHEMBL15032896 | 0.86 | CHRNB4 (0.65) | CHRNB4CHRNA3CHRNB1CHRNB2CHRNB3 | |
| SCHEMBL25594625 | 0.86 | CHRNB4 (0.65) | CHRNB4CHRNA3CHRNB1CHRNB2CHRNB3 | |
| SCHEMBL6521793 | 0.85 | CHRNB1 (0.45) | CHRNB4CHRNA3CHRNB1CHRNB2CHRNB3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 49 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230167110-A1 | 6-HETEROARYLOXY BENZIMIDAZOLES AND AZABENZIMIDAZOLES AS JAK2 INHIBITORS | SCHRÖDINGER, INC. | 2023-06-01 | — | — | US | disclosed |
| WO-2023086319-A1 | 6-HE TERO ARYLOXY BENZIMIDAZOLES AND AZABENZIMIDAZOLES AS JAK2 INHIBITORS | AJAX THERAPEUTICS, INC. (US) | 2023-05-19 | — | — | WO | disclosed |
| WO-2022140527-A1 | 6-HETEROARYLOXY BENZIMIDAZOLES AND AZABENZIMIDAZOLES AS JAK2 INHIBITORS | AJAX THERAPEUTICS, INC. (US) | 2022-06-30 | — | — | WO | disclosed |
| CN-114478366-A | Pyridone derivative and application thereof in medicine | 海思科医药集团股份有限公司 | 2022-05-13 | — | — | CN | disclosed |
| EP-2600874-B1 | PYRIMIDINE COMPOUNDS THAT INHIBIT ANAPLASTIC LYMPHOMA KINASE | AMGEN INC (US) | 2015-03-04 | — | — | EP | disclosed |
| US-8716281-B2 | Pyrimidine compounds that inhibit anaplastic lymphoma kinase | AMGEN INC. (US) | 2014-05-06 | — | — | US | disclosed |
| US-8716281-B2 | Pyrimidine compounds that inhibit anaplastic lymphoma kinase | AMGEN INC. (US) | 2014-05-06 | — | — | US | disclosed |
| US-8642624-B2 | Substituted alkylamine derivatives and methods of use | AMGEN INC. (US) | 2014-02-04 | — | — | US | disclosed |
| US-20130273004-A1 | SUBSTITUTED ALKYLAMINE DERIVATIVES AND METHODS OF USE | AMGEN INC (US) | 2013-10-17 | — | — | US | disclosed |
| EP-1537084-B1 | SUBSTITUTED 2-ALKYLAMINE NICOTINIC AMIDE DERIVATIVES AND USE THERE OF | AMGEN INC (US) | 2013-08-21 | — | — | EP | disclosed |
| US-20040204437-A1 | Substituted arylamine derivatives and methods of use | AMGEN INC. | 2004-10-14 | — | — | US | disclosed |
| US-20040087568-A1 | Substituted anthranilic amide derivatives and methods of use | AMGEN INC. | 2004-05-06 | — | — | US | disclosed |
| US-20030225106-A1 | Substituted alkylamine derivatives and methods of use | AMGEN INC. | 2003-12-04 | — | — | US | disclosed |
| EP-1358161-A2 | N-PYRIDYL CARBOXAMIDE DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | Amgen Inc. (US) | 2003-11-05 | — | — | EP | disclosed |
| US-20030203922-A1 | Substituted amine derivatives and methods of use | AMGEN INC. | 2003-10-30 | — | — | US | disclosed |
| US-20030195230-A1 | Substituted amine derivatives and methods of use | AMGEN INC. | 2003-10-16 | — | — | US | disclosed |
| US-20030134836-A1 | Substituted arylamine derivatives and methods of use | AMGEN INC. | 2003-07-17 | — | — | US | disclosed |
| US-20030125339-A1 | Substituted alkylamine derivatives and methods of use | AMGEN INC. | 2003-07-03 | — | — | US | disclosed |
| US-20020147198-A1 | Substituted arylamine derivatives and methods of use | AMGEN INC. | 2002-10-10 | — | — | US | disclosed |
| WO-2002055501-A2 | N-PYRIDYL CARBOXAMIDE DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | AMGEN INC (US) | 2002-07-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030225106-A1 | Substituted alkylamine derivatives and methods of use | NAT1, PIGO, AADAC | CHRNB4 3031/4885CHRNA3 2615/4885CHRNB1 1732/4885 |
| US-20040204437-A1 | Substituted arylamine derivatives and methods of use | NAT1, AADAC, AHR | CHRNB4 4141/4885CHRNA3 4231/4885CHRNB1 3200/4885 |
| US-20030125339-A1 | Substituted alkylamine derivatives and methods of use | AADAC, NAT1, PIGO | CHRNB4 3504/4885CHRNA3 2996/4885CHRNB1 2153/4885 |
| US-20130273004-A1 | SUBSTITUTED ALKYLAMINE DERIVATIVES AND METHODS OF USE | AADAC, NAT1, PIGO | CHRNB4 3455/4885CHRNA3 2850/4885CHRNB1 2042/4885 |
| US-20030134836-A1 | Substituted arylamine derivatives and methods of use | NAT1, AADAC, AHR | CHRNB4 4141/4885CHRNA3 4231/4885CHRNB1 3200/4885 |
| US-20030203922-A1 | Substituted amine derivatives and methods of use | MAOB, HNMT, FLT4 | CHRNB4 3520/4885CHRNA3 3218/4885CHRNB1 2269/4885 |
| US-20040087568-A1 | Substituted anthranilic amide derivatives and methods of use | AADAC, ASPH, EGLN3 | CHRNB4 4878/4885CHRNA3 4833/4885CHRNB1 4810/4885 |
| US-20230167110-A1 | 6-HETEROARYLOXY BENZIMIDAZOLES AND AZABENZIMIDAZOLES AS JAK2 INHIBITORS | JAK2, JAK3, STAT5B | CHRNB4 4841/4885CHRNA3 4746/4885CHRNB1 4779/4885 |
| US-20020147198-A1 | Substituted arylamine derivatives and methods of use | NAT1, AADAC, AHR | CHRNB4 4141/4885CHRNA3 4231/4885CHRNB1 3200/4885 |
| US-20030195230-A1 | Substituted amine derivatives and methods of use | MAOB, HNMT, FLT4 | CHRNB4 3520/4885CHRNA3 3218/4885CHRNB1 2269/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.